Bicycle Therapeutics (NASDAQ:BCYC) Announces Earnings Results

Bicycle Therapeutics (NASDAQ:BCYC) released its quarterly earnings data on Tuesday. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.10, Briefing.com reports. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Bicycle Therapeutics’s quarterly revenue was down 30.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.16) EPS.

Bicycle Therapeutics Stock Up 3.2 %

BCYC stock traded up $0.35 during trading hours on Wednesday, hitting $11.45. The company’s stock had a trading volume of 77,918 shares, compared to its average volume of 301,898. The company has a market capitalization of $790.62 million, a PE ratio of -3.48 and a beta of 0.93. Bicycle Therapeutics has a 12 month low of $10.91 and a 12 month high of $28.67. The stock has a 50 day moving average price of $13.42 and a two-hundred day moving average price of $19.52.

Insider Buying and Selling

In other news, COO Alistair Milnes sold 4,578 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $64,504.02. Following the transaction, the chief operating officer now owns 100,724 shares of the company’s stock, valued at approximately $1,419,201.16. This trade represents a 4.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bros. Advisors Lp Baker acquired 985,397 shares of Bicycle Therapeutics stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average cost of $13.76 per share, for a total transaction of $13,559,062.72. Following the purchase, the director now directly owns 9,537,643 shares in the company, valued at $131,237,967.68. The trade was a 11.52 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 27,677 shares of company stock valued at $392,413. Company insiders own 8.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday. JMP Securities dropped their price target on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research note on Wednesday, December 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday. Finally, Stephens reiterated an “equal weight” rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $29.14.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.